Patients with previously untreated , locally advanced or metastatic measurable gastric adenocarcinoma were randomly assigned to receive SIri ( irinotecan @ mg/m ( @ ) was administered intravenously ( i.v. ) on day @ and @ , while @ mg/m ( @ ) S-@ was orally administered twice daily for three weeks from days @-@ followed by a two-week pause ) or SPac ( paclitaxel @ mg/m ( @ ) was administered i.v. on day @ and @ , while @ mg/m ( @ ) S-@ was orally administered twice daily for two weeks from day @-@ followed by a one-week pause ) regimen .